Skip to Main Content

Paper Details

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
0
2022
Author NameAffiliation
Donna NeubergDepartment of Data Sciences Dana-Farber Cancer Institute Boston Massachusetts USA.
  • 1 - 1

Datasets

Release 1.2